BridgeBio Pharma's drug infigratinib showed promising results in a Phase 3 clinical trial for treating achondroplasia, increasing children's growth rates and improving body proportionality compared to a placebo. The oral medication could offer a more convenient alternative to existing injectable treatments, and BridgeBio plans to seek regulatory approvals in the U.S. and Europe later this year.
BridgeBio Pharma's oral drug, infigratinib, has shown promising results in a Phase 3 trial for treating achondroplasia, offering a potential alternative to the current injectable treatments with statistically significant improvements in growth rates and body proportionality. While there are challenges with oral administration for young children, the drug's oral form and efficacy could position it for significant market share if approved, with projected peak sales of $1.5 billion. This positions infigratinib as a potentially valuable investment opportunity within the healthtech and biotech sectors, particularly in the competitive dwarfism treatment market.